Yes, if the positive futility analysis is indeed a trigger for this potential regional licensing arrangement and/or equity investment, then having the maturity date of the loan extended out to December 26, 2017 should almost guarantee enough time for the futility analysis to be triggered. 

Lots of unanswered questions. No webcast corporate update since December 2016. Will there be a webcast from Rodman and Renshaw (September 10-12), or any plan for a webcast corporate update in 2017? Lots of ongoing/planned activites with the company listed in the next paragraph. Does the extension of the loan maturity date allow for funding of any of these ongoing/planned activities, or would this potential regional licensing arrangement and/or equity investment need to close first before starting these?

When will we hear details of how BETonMACE trial protocol will be altered for the inclusion of USA patients? How will any changes affect the number of patients, length of trial, # of target MACE events, etc? Will the Phase 2a Renal trial still start in mid-September as currently listed on ClinicalTrials.gov? Will the Fabry Disease Phase 1/2 trial still launch October 2017 as currently listed on ClinicalTrials.gov? Is the plan for PNH trial still alive? When will this rumored new Resverlogix website be launched? What about the IND filing and plans for second compound that was discussed fall of last year? 

This has not been the year of good communication.......more like ill communication.

BearDownAZ